Edition:
United Kingdom

Hutchison China MediTech Ltd (HCM.OQ)

HCM.OQ on NASDAQ Stock Exchange Global Select Market

32.05USD
5:19pm GMT
Change (% chg)

$-1.84 (-5.43%)
Prev Close
$33.89
Open
$33.79
Day's High
$33.81
Day's Low
$31.70
Volume
16,042
Avg. Vol
20,538
52-wk High
$35.87
52-wk Low
$12.67

Select another date:

Wed, Oct 25 2017

China cancer specialist Chi-Med plans $262 mln share offering

LONDON, Oct 25 China-based cancer and immunology drug specialist Hutchison China MediTech, or Chi-Med, said it aimed to offer $262 million of American Depositary Shares, subject to market conditions, to help fund development of its pipeline.

BRIEF-Astrazeneca says co and Chi-med's Savolitinib shows encouraging clinical activity

* Astrazeneca and Chi-med’s Savolitinib shows encouraging clinical activity in 2nd-line EGFR mutation-positive lung cancer with met-amplification

AstraZeneca, Chi-Med take kidney cancer drug into final testing

LONDON AstraZeneca and Hutchison China MediTech said on Thursday they had initiated a global late-stage clinical trial of the experimental drug savolitinib in a relatively rare type of kidney cancer.

Chi-Med steps closer to Chinese pharma first with drug filing

(This June 12 story has been corrected to remove reference to Lilly in paragraph 4)

Chi-Med steps closer to Chinese pharma first with drug filing

(This story corrects to remove reference to Lilly in paragraph 4.)

CORRECTED-Chi-Med steps closer to Chinese pharma first with drug filing

LONDON, June 12 Hutchison China MediTech , the Shanghai-based drugmaker listed in London, is a step closer to winning approval for a modern drug developed in a Chinese lab with the submission of its cancer medicine fruquintinib to China's drug watchdog.

Select another date: